Enhertu: Breast cancer patients denied life-extending drug in NHS row
Jeannie put us in touch with a group of about 20 women who are all in the same position as her.
They range from their early 30s to mid 50s and all have advanced HER2-low breast cancer.
They’re all very keen to stress that they’re not slowly fading away, but are living full and busy lives.
They sent snapshots of their lives, showing them dancing with their kids, or on nights out with their friends. Some are surfers, and there’s a few cold-water swimmers and a sky diver.
They have limited options to get Enhertu – some might be able to access it through private health insurance.
If not, they could pay directly. We’ve heard of quotes ranging from £7,500 to £13,000 every three weeks.
Some told the BBC they were considering the idea of moving to Scotland, where they could get it on the NHS. Jeannie says that’s not an option for her family.
“We shouldn’t be having to think of moving to Scotland or selling our houses,” she says.
“It feels unfair. I should be concentrating on the time I’ve got left and spending time with my family and friends. I should not be campaigning, using the time I’ve got left to fight. I just feel unheard.”
